WO2000000638A2 - Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription - Google Patents

Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription Download PDF

Info

Publication number
WO2000000638A2
WO2000000638A2 PCT/EP1999/004290 EP9904290W WO0000638A2 WO 2000000638 A2 WO2000000638 A2 WO 2000000638A2 EP 9904290 W EP9904290 W EP 9904290W WO 0000638 A2 WO0000638 A2 WO 0000638A2
Authority
WO
WIPO (PCT)
Prior art keywords
primer
rna
target
sequence
transcription
Prior art date
Application number
PCT/EP1999/004290
Other languages
English (en)
Other versions
WO2000000638A3 (fr
Inventor
Peter Theodorus Gerardus Sillekens
Petrus Bernardus Hugo Van Deursen
Wessel Kok
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Priority to AU45156/99A priority Critical patent/AU4515699A/en
Publication of WO2000000638A2 publication Critical patent/WO2000000638A2/fr
Publication of WO2000000638A3 publication Critical patent/WO2000000638A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]

Definitions

  • the present invention concerns a method for tagging the reaction products of transcription-based amplification procedures, and a kit for detecting such tagged nucleic acid amplified in a transcription-based amplification assay.
  • Nucleic acid amplification methods are used in the field of molecular biology and recombinant DNA technology. These methods are used to increase the number of copies of a particular nucleic acid sequence, present in small amounts and often in an environment in which a wide variety of other nucleic acid sequences, both RNA and DNA, are also present.
  • nucleic acid amplification methods are used to facilitate the detection or quantification of nucleic acid and are important for diagnosing for example infectious diseases, inherited diseases and various types of cancer.
  • Nucleic acid amplification methods have also found their applications in other fields such as forensic sciences or archeology where samples are investigated in which nucleic acid may be present in minute amounts, or to establish paternity.
  • PCR Polymerase Chain Reaction
  • RNA double stranded DNA
  • reverse transcriptase A different class of nucleic acid amplification methods are the "transcription-based amplification" techniques.
  • the techniques involve the transcription of multiple RNA copies from a template comprising a promoter recognized by an RNA polymerase. With these methods, multiple RNA copies are transcribed from a DNA template that comprises a functional promoter recognized by the RNA polymerase. Said copies are used as a target again from which a new amount of the DNA template is obtained etc.
  • Such methods have been described by Gingeras et al. in WO88/10315 and Burg et al.
  • thermostable enzymes allow the reaction to be carried out at more elevated temperatures.
  • thermostable method is described in EP 682121 filed in the name of Toyo Boseki KK.
  • RNA-dependent DNA polymerase activity an enzyme activity required to achieve amplification: an RNA-dependent DNA polymerase activity, a DNA-dependent DNA polymerase activity, an RNase (H) activity and an RNA polymerase activity. Some of these activities can be combined in one enzyme so usually only 2 or 3 enzymes are necessary. Enzymes having RNA-dependent DNA polymerase activities are enzymes that synthesize DNA from a RNA template. A DNA-dependent DNA polymerase thus synthesizes DNA from a DNA template.
  • a reverse transcriptase such as AMV (Avian Myeloblastosis Virus) or MMLV (Moloney Murine Leukemia Virus) reverse transcriptase may be used.
  • AMV Allevian Myeloblastosis Virus
  • MMLV Moloney Murine Leukemia Virus
  • DNA-dependent RNA polymerases synthesize multiple RNA copies from a DNA template including a promoter recognized by the RNA polymerase. Examples of RNA polymerases are polymerases from E. coli and bacteriophages T7, T3 and SP6.
  • RNA polymerase commonly used with transcription-based amplification methods
  • T7 RNA polymerase An example of an RNA polymerase commonly used with transcription-based amplification methods is T7 RNA polymerase.
  • the promoter that is incorporated in the template used for transcribing multiple copies of RNA would then be the T7 promoter.
  • the template comprising the promoter has to be created starting from the nucleic acid comprising the target sequence.
  • Said nucleic acid may be present in the starting material that is used as input for the amplification reaction.
  • the nucleic acid present in the starting material will usually contain the target sequence as a part of a much longer sequence. Additional nucleic acid sequences may be present on both the 3'- and the 5'-end of the target sequence.
  • the amplification reaction can be started by bringing together this nucleic acid from the starting material, the appropriate enzymes that together provide the above mentioned activities and at least one, but usually two, oligonucleotide(s). At least one of these oligonucleotides should comprise the sequence of the promoter.
  • RNA single stranded RNA
  • a pair of oligonucleotides that is conveniently used with the methods as described in the prior art would consist of: - a first oligonucleotide ("primer”, usually also referred to as "promoter-oligonucleotide") that is capable of hybridizing to the 3'-end of the target sequence, which oligonucleotide has the sequence of a promoter (preferably the T7 promoter) attached to its 5' end (the hybridizing part of this oligonucleotide has the opposite polarity as the plus RNA used as input material).
  • promoter preferably the T7 promoter
  • oligonucleotide which comprises the 5' end of the target sequence (this oligonucleotide has the same polarity as the plus RNA).
  • detection techniques comprise the introduction of a label directly into the amplificate.
  • a detection may include an additional hybridisation step in order to increase the specificity of the assay.
  • Analysis of transcription-based amplification reaction mixtures may require separation of the target nucleic acid-derived amplicons and the non-specific reaction products.
  • One example by which this can be achieved is subjecting the sample with amplified nucleic acid to gel electrophoresis. Following separation by gel electrophoresis, the gel can be blotted onto a filter and hybridised with a complementary oligonucleotide labelled with a detection moiety.
  • target nucleic acid-derived amplicons are captured onto a solid phase by hybridisation to a complementary oligonucleotide immobilised on the solid phase. Subsequently, the captured amplicons can be detected by a moiety labelled with a reporter molecule.
  • nucleic acid analysis making use of such sandwich hybridisation principle is electrochemiluminescence-based (ECL-based) detection as described by Kenten et al., Clin. Chem. 38, pp 873-879 (1992).
  • ECL-based electrochemiluminescence-based
  • the solid phase is formed by paramagnetic beads and target nucleic acid-derived amplicons bound by specific hybridisation to a complementary oligonucleotide immobilised on the beads can be detected by a second complementary oligonucleotide labelled with the ruthenium chelate Tris(2,2'-bipyridine)ruthenium(ll) (TBR).
  • TBR Tris(2,2'-bipyridine)ruthenium(ll)
  • TPA tripropylamine
  • telomeres Methods for the introduction of a label directly into the amplified nucleic acid, i.e. covalently bound to the reaction product, are well known in the art.
  • one of the primers can be labelled with a suitable detectable moiety which in turn is then incorporated into the amplification product.
  • useful labels include radioisotopes, fluorescent moieties, enzymes or specific binding moieties such as avidin or biotin, as noted for example in US Patent no US-A-4, 879,214.
  • biotinylated oligonucleotide primers in the PCR amplification reaction, for example, reveals biotin- labelled end products, which upon binding to a solid phase by hybrid-capture, can be detected by streptavidin complexed to a reporter molecule like horse radish peroxidase (HRP) or a fluorescent moiety.
  • HRP horse radish peroxidase
  • the oligonucleotide primers employed in a transcription-based amplification reaction do not form an intrinsic part of the single stranded antisense
  • RNA which is generated as the major amplification product. Reaction products from transcription-based amplification reactions, therefore, cannot be labelled by performing the reaction with labelled primers.
  • reaction products from transcription-based amplification reactions therefore, cannot be labelled by performing the reaction with labelled primers.
  • the use of labelled ribonucleotide-5'-triphosphates has been suggested (IBC UK conferences Ltd).
  • a specific hybridisation probe has to be newly developed for each target, based on the particular nucleic acid sequence of that target. This may be a cumbersome, time consuming and expensive procedure, especially if one wants to amplify a large number of different targets or if one wants to use a detection probe with a label such as an ECL label covalently attached.
  • the present invention provides a solution to that problem in that it provides a method for the introduction of a (generic) sequence element into the reaction products of a transcription-based amplification reaction in order to be able to detect that specific element with a (generic) detection probe, independent of the nucleic acid sequence of the target.
  • a specific element is herein referred to as a transcribablenon-target related sequence element.
  • the method of the present invention includes the feature that where for transcription- based amplification methods introduction of labelled primers or mononucieotides is not possible or difficult to achieve, the major amplification product (i.e. single stranded antisense RNA) can be tagged with a certain ribonucleotide segment which is introduced into the amplification product during transcription by making use of a primer which in addition to the target RNA-derived sequence contains an extra non- target related sequence element.
  • a transcribable non-target related sequence element into one or both primers would negatively influence the amplification efficiency of such primers when used in a transcription-based amplification assay. Surp ⁇ singly, it was found that neither the length of such sequence element nor its primary structure appeared to have any impact on the performance of the primer in the amplification reaction.
  • the tag consisting of a stretch of nucleotides can either be added at the 5' end of the upstream primer or between the target RNA-derived sequence and the RNA polymerase promoter segment of the downstream primer, resulting in a tag at the 3' end or the 5' end of the RNA amplicons, respectively.
  • Use of a combination of tagged upstream and downstream primers is possible as well, introducing an extra ribonucleotide segment at either end of the RNA amplicon.
  • the invention thus concerns a method for tagging the reaction products of a transcription-based amplification assay, comprising the steps of adding to a reaction mixture; a. at least one oligonucleotide that can function as a nucleic acid primer for a transcription-based amplification reaction b. appropriate enzymes c. target sequence and subsequently incubating the mixture at an appropriate temperature for an appropriate amount of time in order to accomplish amplification of at least part of the target sequence characterised in that said at least one oligonucleotide contains a transcribable non-target related sequence element.
  • said transcription-based amplification assay is a NASBA assay.
  • said method is characterised in that two oligonucleotides contain a transcribable non-target related sequence element.
  • said method is characterised in that said transcribable non-target related sequence element comprises a nucleic acid sequence selected from the group consisting of SEQ ID # 1-4.
  • amplicons Upon amplification, presence of target nucleic acid-derived amplicons generated in the amplification reaction is usually demonstrated by detecting the amplicons with a labelled probe which can specifically hybridise to the amplicons. It was now found that amplicons could be detected with equal efficiency, sensitivity and specificity irrespective whether a target related nucleic acid sequence or a non-target related sequence, introduced by the above described method, was targeted by the detection probe.
  • extension of oligonucleotides used as primers in transcription- based amplification reactions and subsequent detection of the generated amplicons by means of hybridisation of an oligonucleotide complementary to the sequence element that is thus introduced into the amplicons is feasable and enables the use of a generic detection moiety for target nucleic acids of different origin.
  • the present invention can thus be used for the detection of nucleic acids in a sandwich hybridisation assay in which either the capture probe or the detection probe is complementary to the extra RNA segment introduced into the RNA amplicon. If a universal tagging segment is used for different target RNAs, instead of two target RNA-derived oligonucleotides, one of which functions as the capture probe and the other as the detection probe, only one target RNA-derived oligonucleotide is needed in combination with a second generic oligonucleotide which is complementary to the tag of the RNA amplicons.
  • a preferred embodiment of the present invention is therefore a kit for detecting nucleic acid amplified in a transcription-based amplification assay using the above described method, comprising a nucleic acid probe hybridisable to the transcribable non-target related sequence element or its complement.
  • nucleic acid probe is attached to a detectable label.
  • said detectable label is an ECL label.
  • the present invention can also be used to separate amplicons that carry the extra non-target related sequence from those that do not.
  • Tailing of the upstream primer with a transcribable, non-target-related sequence element reveals RNA amplicons with the non-target related sequence element at their 3' ends.
  • RNA amplicons in transcription-based amplification reactions occurs in the 5' end to
  • the method of the present invention can also be used for tagging a polypeptide with a certain stretch of amino acids such as, for example, hexa-histidine for metal- chelate separation or with an epitope sequence for separation by an immobilised monoclonal antibody (for a review see Jones et al., J. Chromatogr. A 707, pp 3-22 (1995)). This can be achieved by chosing the correct coding sequence for the extra sequence element added to one of the primers used for amplification.
  • RNA transcripts meant for subsequent translation into a polypeptide
  • RNA transcripts By generating RNA transcripts for subsequent translation through transcription- based amplification, tagging of the resulting polypeptide can much easier be achieved, simply by elongation of one or both primers with an appropriate sequence element.
  • Changing the tag of the polypeptide can be achieved by changing the primary structure of the extra sequence element added to the primer or primers used, thereby circumventing the need to generate a new DNA clone which would be much more labour intensive.
  • the method of the invention enables the generic labelling of amplicons. Due to the presence of the generic sequence in the amplicons, the method of the invention also enables the differentiation of contaminating amplicons and target molecules in subsequent amplification reactions.
  • the amplicons generated by the method of the invention will all comprise a generic sequence.
  • the generic sequence that will only be present in contaminating amplicons and not in the target sequence, can be used to separate the contaminating amplicons from the sample.
  • the present invention further comprises a method for counteracting carry-over contamination in transcription based amplification reaction mixtures. Said method comprises tagging the reaction products of a transcription based amplification reaction by adding at least one oligonucleotide that can function as a nucleic acid primer for a transcription-based amplification reaction to the amplification reaction mixture.
  • reaction mixtures can then be checked, prior to amplification, for the presence of tagged reaction products.
  • Said tagged reaction can optionally be removed from the reaction mixture or kept separate from the amplification reaction.
  • the tagged reaction products may be removed by reacting them with a capture- oligonucleotide comprising a complementary sequence.
  • capture oligonucleotides are preferably bound to a solid phase.
  • the solid phase may then be contacted with the reaction mixture under conditions suitable for binding the tagged reaction products to the capture-oligonucieotides.
  • the tagged reaction products When the tagged reaction products are bound to the capture oligonucleotides, they can easily be removed from the reaction mixture or be kept aside during the amplification reaction so that the tagged products with which the sample was contaminated will not participate in the amplification reaction.
  • the reaction mixture, or the sample from which the reaction mixture is prepared may be contacted with the solid phase during work up. For example, during nucleic acid isolation from the sample, but in any event prior to amplification.
  • the solid phase may stay in touch with the reaction mixture during primer addition, and can be separated from the pre-amplification mixture prior to addition of the enzymes necessary for the amplification reaction.
  • the solid phase may have any suitable format.
  • the solid phase may be particulate.
  • the particles, with the tagged reaction products bound thereto, may than be separated from the reaction mixture by filtration.
  • the solid phase may also be composed of magnetic or (super)paramagnetic beads. In that case the solid phase can be separated from the reaction mixture using a magnet.
  • reaction products of a transcription based amplification reaction can be tagged with a sequence that has nothing to do with the sequence of the specific target, i.e. a "generic" sequence", and thus, a detection kit based on said method may, for example, comprise a labeled probe, comprising an oligonucleotide with a sequence that is the complementary of the generic sequence introduced in the reaction products of a transcription based amplification method.
  • the probe can be used in many assays, irrespective of the target sequence or organism to be detected.
  • the same principle can also be used to construct internal standards for transcription based amplification reactions.
  • internal standards are often used. Either to be able to check whether the amplification reaction was carried out correctly or to have a known amount of standard material based on which the amount of a target sequence present in a sample can be determined.
  • the use of internal standards in transcription based amplification reactions is described in EP656955.
  • Quantitative transcription based amplification methods wherein internal standards are co- amplified with the target, using the same primers are described in EP525882 and EP662156.
  • these internal standards are provided to the user and are specific for the target sequence to be amplified, since the standards have to comprise the same primer binding sites as the target sequence within the nucleic acid of the organism to be detected with the kit.
  • kits according to the invention might not be provided with internal standards with said kit, simply, because, while the kit is generic, the standards would have to be target specific.
  • RNA transcripts that can be used as internal standard in a transcription based amplification reaction.
  • an internal standard sequence is tagged with transcribable non-target related sequence elements.
  • the transcribable non-target related sequence elements are used to introduce the target specific primer binding sites into generic internal standards, for the amplification reaction in which the internal standards are to be used.
  • the sequence of the internal standards between the primer binding sites can be chosen by the user. It may resemble the target sequence, but will include specific regions to be able to discriminate it from the target, for example, specific probe binding regions.
  • the internal standards may have the same length as the target or may differ in length from the target sequence.
  • the internal standard Since, eventually, the internal standard will be co-amplified with the target, they can, in the amplification reaction, be tagged with a transcribable non-target related sequence element, for example, to allow them to hybridize with the same generically labelled probe as the target.
  • the primer binding sites for the eventual amplification reaction (for the sake of clarity referred to as "A” and "B") in which the internal standards are to be used can be introduced trough transcription based amplification reactions with primers that include the sequences "A" and/or "B” or the complement thereof as an additional sequence, i.e. as a transcribable non-taget related sequence element.
  • RNA on which the internal standards are based will be referred to as "generic input RNA".
  • said RNA may have any sequence desired by the user. It may resemble the target is certain ways, but will be distinguishable therefrom as well. For example, because it has its own specific probe binding site, or because it comprises a mutation based on which it can be distinguished from the target (or rather; the amplification products derived therefrom) or because it differs in length from the target.
  • This generic input RNA may be subjected to a first transcription based amplification reaction wherein a first and second primer are used and said first primer comprises a sequence homologous to the 5' region of the generic input RNA and further comprising a 5' tail, said 5' tail comprising a primer region A homologous to the target RNA, and a second primer comprising a sequence complementary to the 3' end of the generic input RNA, said second primer further comprising a sequence of a promoter recognised by an RNA polymerase.
  • a first and second primer are used and said first primer comprises a sequence homologous to the 5' region of the generic input RNA and further comprising a 5' tail, said 5' tail comprising a primer region A homologous to the target RNA, and a second primer comprising a sequence complementary to the 3' end of the generic input RNA, said second primer further comprising a sequence of a promoter recognised by an RNA polymerase.
  • these reaction products may be subjected to a second transcription based amplification reaction wherein a third and fourth primer are used.
  • the primer B region is introduced.
  • Said third primer comprises the sequence of the primer A region and the sequence of a promoter for a RNA polymerase.
  • Said fourth primer comprises a sequence complementary to the 3' region of the generic input RNA and further comprises a sequence homologous to the primer B region.
  • the primer A region and primer B region are also present in the target RNA and thus these internal standards can now be used in an amplification reaction together with the target. Either as an internal control for the reaction or as a calibrator in a quantitative reaction. It will be evident that many variations on the above described reaction scheme are possible, all based on the same principle, namely the introduction of the primer binding sites by using them as a "transcribable, non-target related sequence element" in the method of the invention, and that all these variations are likewise part of the present invention.
  • a minimal length of at around 100 nucleotides is preferred for efficient amplification of the target nucleic acid sequence. If such a minimal length is not available, the length of the amplification product can artificially be extended by introducing extra non- target related sequences into one or both primers used for transcription-based amplification of that specific target nucleic acid.
  • a person skilled in the art would recognise that the above is especially useful in one or more of the following situations.
  • RNAs like the recently described 3' non- coding terminal sequence of the hepatitis C virus (HCV) genomic RNA as described by Kolykhalov et al., J. Virol. 70, pp 3363-3371 (1996), which is highly conserved but only 98 nucleotides in length.
  • HCV hepatitis C virus
  • this 3' terminal sequence is preceded by homopolymer tracts of either poly(U) or polypyrimidine stretches consisting of mainly U residues with occasional interspersed C residues.
  • homopolymeric sequences are not well suited as a primer annealing site. Therefore, the target segment for amplification cannot be expanded beyond this 3' terminal stretch of 98 nucleotides which by itself has not an ideal length for efficient transcription-based amplification. Therefore, artificial extension of the target segment by elongation of one or both primers can be beneficial for more efficient transcription-based amplification.
  • Figure 1 The figure shows a photographic representation of an enzyme-labeled gel assay (ELGA) wherein primers with a transcribable non-target related sequence elements are analysed for their performance in a NASBA assay.
  • P2 U1A P2 primer with 5' end elongations of different sizes.
  • U1A P2 primers with elongations of 15 (P2 + 15), 20 (P2 + 20) and 24 (P2 + 24) nucleotides were were compared to a standard P2 primer (P2) for the amplification of U1A Sc-RNA. Reaction products were analysed by ELGA.
  • Figure 2 Preparation of internal standards using two rounds of transcription based amplification.
  • Oligonucleotide primers and probes were synthesised on a PCR-MATE 391 DNA synthesiser (Applied Biosystems) using phosphoramadite biochemistry.
  • Amplification primers were purified by electrophoretically separating the crude oligonucleotide solutions over a 20% polyacrylamide/7M Urea slabgel and subsequent elution of the full-length oligonucleotide from the corresponding gel band. After elution from the gel slices and concentration by ethanol precipitation, primers were dissolved in Milli-Q water and concentrations determined by OD(260 nm) measurement.
  • Oligonucleotide probes for ELGA detection were synthesised with a 5'-amino link (Aminolink 2; Applied Biosystems) and conjugated with Horse Radish Peroxidase (Boehringer) by coupling the enzyme to an amino link oligonucleotide using the cross-linking reagent SPDP (Pharmacia). Unbound HRP was removed by passing the reaction mixture over a Qiagen Tip-100 column (Qiagen). The HRP-labelled oligonucleotide was further purified by slabgel electrophoresis. The amount of HRP- conjugated oligonucleotide was calculated from OD(260 nm) and OD(400 nm) measurement.
  • oligonucleotide probes were synthesised with a 5'-amino link and conjugated with the ECL label Tris(2,2'-bipyridine)ruthenium(ll) (TBR) by incubating the amino link oligonucleotides with TAG NHS-Esther (Igen). Unbound label was removed by passing the reaction mixture over a Qiagen Tip-100 column (Qiagen). The amount of ECL-labelled oligonucleotide was calculated from OD(260 nm) and OD(460 nm) measurements. The solutions were stored at -70° C and used without further purification.
  • TBR Tris(2,2'-bipyridine)ruthenium(ll)
  • Example 2 Isolation of total nucleic acid from blood compartments.
  • one volume of plasma or EDTA-anticoagulated whole blood was added to 9 volumes of Lysis buffer [50 mM Tris-Hydrochloric acid (pH 6.4); 20 mM EDTA; 1.3 % (w/v) Triton X-100; 5.25 M Guanidine thiocyanate].
  • Lysis buffer 50 mM Tris-Hydrochloric acid (pH 6.4); 20 mM EDTA; 1.3 % (w/v) Triton X-100; 5.25 M Guanidine thiocyanate.
  • 100 ⁇ l of plasma or 1 ml of whole blood were used.
  • the suspension was incubated during 10 minutes at room temperature with regular vortexing. Nucleic acid bound to the silica was spun down by centrifugation.
  • Pelleted silica particles were washed twice with 1 ml GuSCN wash buffer [50 mM Tris-Hydrochloric acid (pH 6.4); 5.25 M Guanidine thiocyanate], followed by two washing steps with 1 ml 70 % ethanol and a single washing step with 1 ml acetone. After each washing step, the suspension was briefly centrifuged and the silica pellet was resuspended in the next washing solution by thorough mixing. After removal of the acetone, the silica particles were dried by incubation at 56° C in a heating block during 10 minutes.
  • GuSCN wash buffer 50 mM Tris-Hydrochloric acid (pH 6.4); 5.25 M Guanidine thiocyanate
  • Nucleic acid was eluted from the silica particles by incubation in 50 ⁇ l Elution buffer [1 mM Tris-Hydrochloric acid (pH 8.5)] at 56° C during 10 minutes. Finally, the silica particles were spun down again and the supernatant was carefully pipetted into fresh reaction tubes avoiding any carry-over of silica. Extracted nucleic acid samples were stored at -70° C until use.
  • Example 3 NASBA amplification.
  • a premix was generated by reconstituting a lyophilised Primer accusphere containing the necessary ingredients for a NASBA reaction in Primer diluent.
  • this premix [80 mM Tris-Hydrochloric acid (pH 8.5); 140 mM Potassium chloride; 24 mM Magnesium chloride; 10 mM DTT; 2 mM of each dNTP; 4 mM of ATP, CTP and UTP; 3 mM of GTP; 1 mM of ITP; 3% (w/v) Sucrose; 1% (w/v) Mannitol; 1 % Dextrane T40; 0.4 ⁇ M of each primer] 10 ⁇ l was added to 5 ⁇ l nucleic acid solution and incubated during 5 minutes at 65° C.
  • reaction tubes were incubated at 41 ° C during 5 minutes before 5 ⁇ l Enzyme mix [32 units T7 RNA polymerase; 6.4 units AMV reverse transcriptase; 0.08 unit RNase H; 2.1 ⁇ g BSA; 20 mM DTT; 1.5 M Sorbitol] was added. After the final addition, tubes were mixed by gentle tapping, centrifuged, and incubated at 41 ° C during 90 minutes. Reactions were stopped by storing them at -20° C.
  • Example 4 Analysis of NASBA amplified reaction products by enzyme-linked gel assay (ELGA).
  • NASBA reaction products were hybridised to a target RNA-specific horseradish peroxidase (HRP) 5'-labelled oligonucleotide probe by mixing 2 ⁇ l of a NASBA reaction with 1 ⁇ l 5x SSC [1x SSC is 150 mM Sodium chloride; 15 mM Sodium citrate], 1 ⁇ l concentrated loading buffer [25% (v/v) Glycerol; 10 mM Sodium phosphate buffer (pH 7.0); 0.05% Bromophenol blue; 0.01 % Xylene cyanol], and 1 ⁇ l HRP-labelled oligonucleotide stock solution (containing about 10 10 molecules per ⁇ l), followed by incubation at 41 ° C during 15 minutes.
  • HRP-labelled oligonucleotide stock solution containing about 10 10 molecules per ⁇ l
  • Example 5 Analysis of NASBA amplified reaction products by ECL detection.
  • detection reagents were prepared by vortexing a capture probe solution, containing biotinylated capture probe immobilised on streptavidin-coated paramagnetic beads (Dynal), until an opaque solution was formed and subsequently mixing 10 ⁇ l of this suspension (containing 3.4x10 5 beads loaded with capture probe) and 10 ⁇ l of an ECL labelled probe solution (containing 3.4x10 11 molecules of ECL labelled probe) into fresh reaction tubes. To these mixtures, 5 ⁇ l of an appropriately diluted NASBA reaction was added and incubated during 30 minutes at 41 ° C. Typically, 20-fold diluted reaction mixtures were used. During hybridisation, the tubes were mixed every 10 minutes. Subsequently, 300 ⁇ l NASBA QR System Assay Buffer (Organon Teknika) was added to each hybridisation tube and the tubes were positioned in a NASBA QR System for automated reading of ECL signals.
  • NASBA QR System Assay Buffer Organon Teknika
  • Example 6 Length of the upstream primer elongation.
  • U1A SC-RNA an artificial in vitro generated RNA consisting of a 132 nucleotides HIV-1 fragment (comprising nucleotides 1015 to 1146 of the 5' noncoding region of pv22; see Muir et al., J. Clin. Microbiol. 31., pp31-38 (1993)) flanked by parts of the mRNA encoding the U1 small nuclear ribonucleoprotein (snRNP) particle-specific A protein (U1A), was used in a model system.
  • snRNP small nuclear ribonucleoprotein
  • a P2 primer encompassing 23 nucleotides of the U1A mRNA sequence (nucleotides 378 to 400; see Sillekens et al., EMBO J. 6, pp 3841- 3848 (1987)) was synthesised together with three variants of this primer containing elongations of different sizes at their 5' ends which were not related to the target RNA (Table 1 ).
  • RNA-derived sequence Compared to a normal P2 primer only consisting of a target RNA-derived sequence (P2), no significant influence was observed on the efficiency of amplification when the P2 primer was elongated at its 5' end with a non-target RNA specific sequence, irrespective of the length of the elongation (15, 20 or 24 nucleotides for P2+15, P2+20, and P2+24, respectively). More or less arbitrarily, the extension of 20 nucleotides was chosen for further analyses.
  • Example 7 Composition of the upstream primer elongation. Two extensions with an identical length of 20 nucleotides (see Example 1 ), but with a different primary structure were tested for the amplification of several target RNAs and subsequent detection of the generated RNA amplicons. The primer extensions that were used for the NASBA P2 primers are shown in Table 2.
  • extension 20A and 20B To compare extensions 20A and 20B (Table 2), standard NASBA primer pairs consisting of a regular P1 primer (with a T7 RNA polymerase promoter sequence) and P2 primer were compared to NASBA primer pairs consisting of the same P1 primer but for which the regular P2 primer sequence at its 5' end was elongated with either extension 20A or 20B.
  • Target RNA sequences for which this primer pair comparison was made were the U1A SC-RNA as described in Example 1 , the mRNAs encoding the major immediate early antigen (IE1 mRNA) or a phosphorylated structural protein of 67 kDa (pp67) of the human cytomegalovirus (HCMV).
  • Serial 10 fold dilutions of in vitro generated RNA for each of the targets was prepared and, subsequently, aliquots of each dilution were used in amplification reactions employing either the standard NASBA primer pair or the primer pairs with the elongated P2 primers (P2+20A, P2+20B).
  • RNA amplicons were analysed by electrochemiiuminescence-based detection, using a capture probe and an ECL- labelled detection probe which both were complementary to the target RNA-derived amplicon sequences.
  • electrochemiiuminescence-based detection using a capture probe and an ECL- labelled detection probe which both were complementary to the target RNA-derived amplicon sequences.
  • ECL- labelled detection probe which both were complementary to the target RNA-derived amplicon sequences.
  • results for the different target RNAs are summarised in Tables 3-5.
  • PLRV RNA in quantities of 10 5 , 10 4 , or 10 3 molecules was spiked to a mixture of 100 ⁇ l plasma in 900 ⁇ l Lysis buffer or 1 ml of whole blood in 9 ml of Lysis buffer. Subsequently, total nucleic acid was isolated from the samples using silica-based extraction (see above). The resulting nucleic acid extracts were amplified in NASBA- based amplification reactions employing either the standard PLRV primer pair or the primer pairs with the elongated P2 primers (P2+20A and P2+20B; see also Table 1 ).
  • RNA-specific capture probe For the analysis of the amplification reaction mixtures by ECL detection, a target RNA-specific capture probe and a target RNA-specific ECL probe were used. For each primer pair, final scores for the different target RNA input levels, which were each tested in duplicate, are summarised in Table 6 (plasma background) and Table 7 (whole blood background).
  • the final outcome of the analysis of a given specimen for the presence of a certain target RNA by NASBA-based amplification is the total of amplification and subsequent detection of the amplicons generated from the target RNA. Influence of the P2 primer elongation in the amplification reaction appeared to be negligible (see above). Next, influence on the detection part of the analysis was investigated. Therefore, standard ECL detection employing a target RNA-derived capture probe as well as a target RNA-derived ECL detection probe was compared to ECL detection in which the same target RNA-derived capture probe was used but the target RNA- specific ECL detection probe was replaced by an ECL detection probe that was identical to the primary structure of the P2 elongation.
  • Tables 8-10 show that in principle specific ECL detection of NASBA amplicons is possible when using a combination of two oligonucleotides, one of which is specific for the target RNA, whereas the other is complementary to a non- target RNA sequence which is introduced into the RNA amplicons by elongation of the P2 primer. Furthermore, Tables 8 and 9 show that this detection can be equal to a standard ECL detection format employing two target RNA-specific oligonucleotides and can be varied with respect to the primary structure of the stretch of nucleotides used for the elongation of the P2 primer.
  • Results shown in Table 10 demonstrate that occasionally further optimisation of the detection procedure might improve for certain capture probe/ECL detection probe combinations. Hybridisation at a higher temperature and/or the use of another capture probe might solve the problem of an unusually high background as observed for the ECL probe hybridising to the 20B extension when used in combination with the biotinylated capture probe for PLRV RNA-derived amplicons chosen for this experiment (Table 10).
  • Table 1 P2 primers for NASBA amplification of U1A SC-RNA.
  • nt nucleotides
  • Table 3 Comparison of standard P2 primer with elongated P2 primers for U1 A SC-RNA.
  • Table 4 Comparison of standard P2 primer with elongated P2 primers for IE1 mRNA.
  • Table 5 Comparison of standard P2 primer with elongated P2 primers for pp67 mRNA.
  • Table 8 Comparison of ECL detection formats for U1A SC-RNA-derived NASBA amplicons.
  • Table 9 Comparison of ECL detection formats for HCMV pp67 mRNA-derived NASBA amplicons.

Abstract

L'invention concerne une méthode de marquage des produits de réaction de procédés d'amplification fondés sur la transcription. L'invention concerne également une trousse permettant de détecter un acide nucléique marqué et amplifié dans un dosage d'amplification fondée sur la transcription. La méthode selon l'invention est caractérisée en ce que des amplicons d'ARN sont produits par amplification fondée sur la transcription. Des éléments de séquence susceptibles d'être transcrits et non liés à des cibles sont introduits dans au moins une des deux amorces utilisées dans l'amplification fondée sur la transcription, lesquels sont transcrits dans les amplicons d'ARN. En particulier, les éléments de séquence supplémentaires ayant été ainsi introduits dans les amplicons, peuvent servir à détecter les amplicons, à choisir spécifiquement des amplicons, à rallonger artificiellement les amplicons ou à marquer des polypeptides traduits à partir d'amplicons d'ARN produits par amplification fondée sur la transcription.
PCT/EP1999/004290 1998-06-26 1999-06-21 Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription WO2000000638A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45156/99A AU4515699A (en) 1998-06-26 1999-06-21 Tagging of rna amplicons generated by transcription-based amplification

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202142.0 1998-06-26
EP98202142 1998-06-26

Publications (2)

Publication Number Publication Date
WO2000000638A2 true WO2000000638A2 (fr) 2000-01-06
WO2000000638A3 WO2000000638A3 (fr) 2000-04-20

Family

ID=8233852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/004290 WO2000000638A2 (fr) 1998-06-26 1999-06-21 Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription

Country Status (2)

Country Link
AU (1) AU4515699A (fr)
WO (1) WO2000000638A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308521A1 (fr) * 2001-10-30 2003-05-07 Hong Kong DNA Chips Limited Procédé pour détecter le virus de la fièvre aphteuse et en kit
WO2003057927A2 (fr) * 2002-01-07 2003-07-17 Norchip A/S Detection d'arnm a partir du gene e6 de virus du papillome humain
WO2003070986A1 (fr) * 2002-02-20 2003-08-28 Biomolecular Research Solutions Pty Ltd Procede ameliore d'analyse d'echantillons d'acides nucleiques
JP2004509648A (ja) * 2000-10-05 2004-04-02 ホンコン　ディーエヌエー　チップス　リミティド 非病原性又は病原性インフルエンザａサブタイプｈ５ウイルス検出キット
WO2005071117A2 (fr) 2004-01-23 2005-08-04 Biomerieux, Inc. Amorces et sondes configurees pour permettre une amplification et une detection efficaces de la region non traduisante 3' du vhc
US7553623B2 (en) 2002-01-07 2009-06-30 Norchip A/S Method for detecting human papillomavirus mRNA
US7833716B2 (en) 2006-06-06 2010-11-16 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
EP2263799A2 (fr) * 2000-09-15 2010-12-22 Norchip A/S Système de chambre de réaction microfabriqué
US8198027B2 (en) 2006-12-21 2012-06-12 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US8512955B2 (en) 2009-07-01 2013-08-20 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US10233483B2 (en) 2013-07-03 2019-03-19 Qvella Corporation Methods of targeted antibiotic susceptibility testing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008800A1 (fr) * 1990-11-13 1992-05-29 Siska Diagnostics, Inc. Amplification d'acides nucleiques par replication bi-enzymatique auto-entretenue de sequences
WO1995002067A1 (fr) * 1993-07-09 1995-01-19 Akzo Nobel N.V. Procede ameliore de quantification de l'acide nucleique
WO1996002668A1 (fr) * 1994-07-15 1996-02-01 Azco Nobel N.V. Utilisation d'arn polymerase pour ameliorer un procede d'amplification d'acide nucleique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008800A1 (fr) * 1990-11-13 1992-05-29 Siska Diagnostics, Inc. Amplification d'acides nucleiques par replication bi-enzymatique auto-entretenue de sequences
WO1995002067A1 (fr) * 1993-07-09 1995-01-19 Akzo Nobel N.V. Procede ameliore de quantification de l'acide nucleique
WO1996002668A1 (fr) * 1994-07-15 1996-02-01 Azco Nobel N.V. Utilisation d'arn polymerase pour ameliorer un procede d'amplification d'acide nucleique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GEMEN VAN B ET AL: "A ONE-TUBE QUANTITATIVE HIV-1 RNA NASBA NUCLEIC ACID AMPLIFICATION ASSAY USING ELECTROCHEMILUMINESCENT (ECL) LABELLED PROBES" JOURNAL OF VIROLOGICAL METHODS, vol. 49, 1 January 1994 (1994-01-01), pages 157-167, XP000600186 *
KENTEN J H ET AL: "IMPROVED ELECTROCHEMILUMINESCENT LABEL FOR DNA PROBE ASSAYS: RAPID QUANTITATIVE ASSAYS OF HIV-1 POLYMERASE CHAIN REACTION PRODUCTS" CLINICAL CHEMISTRY, vol. 38, no. 6, 1992, pages 873-879, XP000606988 *
LIVACHE T ET AL: "DETECTION OF HIV1 DNA IN BIOLOGICAL SAMPLESS BY AN HOMOGENEOUS ASSAY: FLUORESCENCE MEASUREMENT OF DOUBLE-STRANDED RNA SYNTHESIZED FROM AMPLIFIED DNA" ANALYTICAL BIOCHEMISTRY,US,ACADEMIC PRESS, SAN DIEGO, CA, vol. 217, no. 2, 1 March 1994 (1994-03-01), pages 248-254, XP000425612 ISSN: 0003-2697 *
SECCHIERO P ET AL: "QUANTITATIVE PCR FOR HUMAN HERPESVIRUSES 6 AND 7" JOURNAL OF CLINICAL MICROBIOLOGY,US,WASHINGTON, DC, vol. 33, no. 8, 1 August 1995 (1995-08-01), pages 2124-2130, XP000564243 ISSN: 0095-1137 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2263799A2 (fr) * 2000-09-15 2010-12-22 Norchip A/S Système de chambre de réaction microfabriqué
JP2012191943A (ja) * 2000-10-05 2012-10-11 Hai Kang Life Corp Ltd 非病原性又は病原性インフルエンザａサブタイプｈ５ウイルス検出キット
US7611837B2 (en) 2000-10-05 2009-11-03 Hai Kang Life Corporation Ltd. Kit for detecting non-pathogenic or pathogenic influenza a subtype h5 virus
JP2004509648A (ja) * 2000-10-05 2004-04-02 ホンコン　ディーエヌエー　チップス　リミティド 非病原性又は病原性インフルエンザａサブタイプｈ５ウイルス検出キット
EP1330553A4 (fr) * 2000-10-05 2004-12-08 Hong Kong Dna Chips Ltd Trousse destinee a la detection d'un virus grippal de type a et de sous-type h5 non pathogene ou pathogene
EP1308521A1 (fr) * 2001-10-30 2003-05-07 Hong Kong DNA Chips Limited Procédé pour détecter le virus de la fièvre aphteuse et en kit
US7553623B2 (en) 2002-01-07 2009-06-30 Norchip A/S Method for detecting human papillomavirus mRNA
WO2003057927A2 (fr) * 2002-01-07 2003-07-17 Norchip A/S Detection d'arnm a partir du gene e6 de virus du papillome humain
WO2003057927A3 (fr) * 2002-01-07 2003-11-06 Norchip As Detection d'arnm a partir du gene e6 de virus du papillome humain
US7812144B2 (en) 2002-01-07 2010-10-12 Norchip A/S Method for detecting human papillomavirus mRNA
US8420314B2 (en) 2002-01-07 2013-04-16 Norchip A/S Method for detecting human papillomavirus mRNA
WO2003070986A1 (fr) * 2002-02-20 2003-08-28 Biomolecular Research Solutions Pty Ltd Procede ameliore d'analyse d'echantillons d'acides nucleiques
WO2005071117A2 (fr) 2004-01-23 2005-08-04 Biomerieux, Inc. Amorces et sondes configurees pour permettre une amplification et une detection efficaces de la region non traduisante 3' du vhc
WO2005071117A3 (fr) * 2004-01-23 2006-04-20 Bio Merieux Inc Amorces et sondes configurees pour permettre une amplification et une detection efficaces de la region non traduisante 3' du vhc
US8580510B2 (en) 2006-06-06 2013-11-12 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
US10167500B2 (en) 2006-06-06 2019-01-01 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
US8034570B2 (en) 2006-06-06 2011-10-11 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
USRE48909E1 (en) 2006-06-06 2022-02-01 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
US7833716B2 (en) 2006-06-06 2010-11-16 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
US9284549B2 (en) 2006-06-06 2016-03-15 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
US8278052B2 (en) 2006-06-06 2012-10-02 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
US8198027B2 (en) 2006-12-21 2012-06-12 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US8642268B2 (en) 2006-12-21 2014-02-04 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US10415092B2 (en) 2006-12-21 2019-09-17 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US9677135B2 (en) 2006-12-21 2017-06-13 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US10407723B2 (en) 2006-12-21 2019-09-10 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US9399796B2 (en) 2009-07-01 2016-07-26 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US10119163B2 (en) 2009-07-01 2018-11-06 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US9169512B2 (en) 2009-07-01 2015-10-27 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US10724085B2 (en) 2009-07-01 2020-07-28 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US8512955B2 (en) 2009-07-01 2013-08-20 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
US10233483B2 (en) 2013-07-03 2019-03-19 Qvella Corporation Methods of targeted antibiotic susceptibility testing

Also Published As

Publication number Publication date
AU4515699A (en) 2000-01-17
WO2000000638A3 (fr) 2000-04-20

Similar Documents

Publication Publication Date Title
CA2299275C (fr) Sequences nucleotidiques pouvant etre utilisees comme amorces et comme sondes au cours de l'amplification et de la detection de tous les sous-types du vih-1
US5849547A (en) Method for nucleic acid amplification by transcription using displacement, and reagents and kit therefor
JP2846018B2 (ja) 核酸配列の増幅および検出
AU647411B2 (en) Enhanced nucleic acid amplification process
US5795715A (en) Process for preparing double-stranded RNA, and its applications
JP2005508599A (ja) 核酸の増幅方法
EP0469755A1 (fr) Procédé de production d'un polynucléotide pour utilisation dans une amplification à l'aide d'une seule amorce
JPH025864A (ja) 核酸増幅方法
JP2001095590A (ja) 核酸ハイブリダイゼーションアッセイのためのプローブ
JP2001521373A (ja) 核酸増幅法：ハイブリダイゼーションシグナル増幅法（ｈｓａｍ）
JP2011505129A (ja) 核酸と信号プローブの同時等温増幅を用いた核酸の検出方法
US7105318B2 (en) Specific and sensitive nucleic acid detection method
EP0682715A1 (fr) Kits et dosages diagnostiques destines a l'arn et effectues a l'aide de sondes binaires d'arn et d'une arn-ligase arn-dependante
JP4727771B2 (ja) 増幅によるクラミジア・トラコマティスの分析およびクラミジア・トラコマティスの核酸の検出
WO2000000638A2 (fr) Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription
O’Meara et al. Cooperative oligonucleotides mediating direct capture of hepatitis C virus RNA from serum
KR19980070560A (ko) 인간 면역결핍 바이러스 1형 검출용 프라이머
JP4553412B2 (ja) マイコプラズマ・ニューモニエ（Ｍｙｃｏｐｌａｓｍａｐｎｅｕｍｏｎｉａｅ）の増幅、検出および型別のためのプライマーおよびプローブ
US5869260A (en) Nucleic acid-antibody constructs and their use in antigen detection
JPH04234999A (ja) Ｑベータレプリカーゼを使用する選択的増幅系
WO1995006753A1 (fr) Procede et compositions de detection par hybridation specifique d'amorces en phase solide de produits de pcr
CA2281793C (fr) Oligonucleotides pouvant etre utilises dans l'amplification et la detection de l'acide nucleique de cytomegalovirus (cmv)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA ID JP KR US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA ID JP KR US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA

CR1 Correction of entry in section i

Free format text: PAT. BUL. 01/2002 UNDER (25) AND (26) REPLACE "FRENCH" BY "ENGLISH"